# CheckMate 7DX (NCT04100018)

> A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab
- Indication: androgen receptor pathway inhibitor-pretreated metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04100018
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Prostate Cancer
- Interventions: Nivolumab; Prednisone; Docetaxel; Placebo
- Enrollment: 1030
- Primary outcome: Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on CheckMate 7DX so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=checkmate-7dx-nct04100018